Immune cell function testing for advanced solid tumors
Part of Cancer, Immune system & allergy clinical trials.
This study looks at how well your immune cells work before and during immunotherapy treatment. It aims to help doctors understand why some patients respond better to these treatments, which could improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have an advanced or metastatic solid tumor (any type).
- You are about to start standard treatment with an immunotherapy drug (such as a PD-1, PD-L1, or CTLA-4 inhibitor), either alone or with chemotherapy.
- You are not receiving immunotherapy combined with targeted therapy.
- You have not had chemotherapy in the 21 days before starting immunotherapy.
- You are not pregnant or breastfeeding, and you agree to follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests a combination of two investigational drugs (IMM2510 and IMM01) that work with your immune system to fight cancer. It may help people with advanced solid tumors who have not responded to other treatments.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.